期刊文献+

发挥医保对医药创新引领作用的路径研究:建立医保创新药物发展基金的设想 被引量:2

Study on the Path of Medical Insurance's Encouragement and Guidance on Pharmaceutical Industry Innovation: The Conception of “Medical Insurance Innovative Drug Development Fund”
原文传递
导出
摘要 我国创新药医保覆盖率低,未能充分发挥医保对医药创新的激励作用。发达国家常采用补充医疗保险的形式对创新药进行支付,有效地促进了医药再创新进程。通过参考国外典型补充保险制度,提出建立我国"创新药物发展基金"的设想,并从基金设立、运作、维持三方面构建"创新药物发展基金"基本架构,为发挥医保对医药产业创新的激励与引导作用设计新路径。 Because of low coverage of innovative drugs, medical insurance payment could not play an incentive role on innovative drugs. Foreign developed countries often adopt the form of supplementary medical insurance to pay for innovative drugs, promoting the process of pharmaceutical re-innovation effectively. It delivered a conception of “Medical Insurance Innovative Drug Development Fund” referring to typical supplementary insurance system in foreign countries. It constructed the basic framework of “Medical Insurance Innovative Drug Development Fund” based on fund establishment, operation and maintenance, expecting to design a new approach to bring into full play the medical insurance’s encouragement and guidance on pharmaceutical industry innovation.
作者 孙圆圆 魏靖哲 蒋蓉 邵蓉 SUN Yuan-yuan;WEI Jing-zhe;JIANG-rong
出处 《中国卫生经济》 北大核心 2018年第12期33-36,共4页 Chinese Health Economics
基金 2015年度国家社科基金重大项目(第二批)(15ZDB167)
关键词 医疗保险 医保创新药物发展基金 医药创新 medical insurance Medical Insurance Innovative Drug Development Fund drug innovation
  • 相关文献

参考文献3

二级参考文献14

  • 1马爱霞,马丽斌.国外药物经济学在药品定价管制中的应用及对我国的启示[J].上海医药,2006,27(11):510-512. 被引量:4
  • 2Private Health Insurance in OECD Countries - ISBN 92-64-01563-9, OECD 2004.
  • 3所有关于美国保险覆盖人群的数字均来源于美国人口普查局2001年3月的报告:”CurrentPopulationSurvey”.
  • 4Annie L. Mach, Bernadette Fernandez (2016), "Private Health Insurance Market Reforms in the Patient Protection and Affordable Care Act (ACA)" , February 10, 2016, Congressional Research Service.
  • 5Hamilton Moses III, MD (2013), "The Anatomy of Health Care In the United States" , The Journal of American Medical Association, November 13. 2013. Volume 310. Number 18.
  • 6Yim E Y, Lim S H, Oh M J, et al. Assessment of pharmacoeconomic evalua- tions submitted for reimbursement in Korea. [ J ]. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research,2012,15 (1Suppl) : S104.
  • 7Morrison E E, Webb D J. UK Health Technology Assessment and Value Based Pricing[ M]. Pharmaceutical Prices in the 21st Century. Springer International Publishing, 2015 : 371-388.
  • 8Afschin G. Convergence of decision rules for value-based pricing of new inno-vative drugs[ J]. Expert Review of Pharmacoeconomics & Outcomes Research,2015,15(2):209-213.
  • 9Erntoft S. Pharmaceutical priority setting and the use of health economic evalu- ations : A systematic literature review [ J ]. Value in Health, 2011, 14 (4) : 587-599.
  • 10Blankart C R,Stargardt T, Schreyogg J. PSY58 Availability of and access to or- phan drugs:An international comparison of pharmaceutical treatments for pul- monary arterial hypertension, Fabry disease, hereditary angioedema and chronicmyeloid leukaemia[ J ]. Pharmacoeconomics ,2010,13 ( 7 ) :63-82.

共引文献12

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部